General Information:

Id: 1,996 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Metabolic syndrome
Obesity - [OMIM]
Rattus norvegicus
male
obese Zucker rat (fa/fa)
article
Reference: Munoz MC et al.(2009) Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J. Hypertens. 27: 2409-2420 [PMID: 19901849]

Interaction Information:

Comment Obese Zucker rats displayed hyperglycemia, hypertriglyceridemia, hyperinsulinemia and hypercholesterolemia and increased systolic blood pressure (SBP) together with decreased activation of insulin signaling through the insulin receptor/insulin receptor substrate-1/phosphatidylinositol 3 kinase/Akt pathway in adipose tissue as well as increased adipocytes size, macrophage infiltration and augmented levels of inflammatory mediators such tumor necrosis factor-alpha, monocyte chemoattractant protein-1 and Ang II. Chronic irbesartan (an Ang II receptor blocker) treatment resulted in an improvement of all alterations. Long-term selective Ang II blockade ameliorates insulin resistance in adipose tissue from a model of metabolic syndrome via a mechanism that could involve the modulation of insulin signaling.
Formal Description
Interaction-ID: 15754

drug/chemical compound

Irbesartan

decreases_quantity of

gene/protein

Angiotensin II

in obese Zucker rats
Drugbank entries Show/Hide entries for Irbesartan